Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies

Until now, a disease-modifying therapy (DMT) that has an ability to slow or arrest Alzheimer's disease (AD) progression has not been developed, and all clinical trials involving AD patients enrolled by clinical assessment alone also have not been successful. Given the growing consensus that the...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Korean J Physiol Pharmacol
Huvudupphovsmän: Kang, Ju-Hee, Ryoo, Na-Young, Shin, Dong Wun, Trojanowski, John Q, Shaw, Leslie M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: The Korean Physiological Society and The Korean Society of Pharmacology 2014
Ämnen:
Review Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4296032/
https://ncbi.nlm.nih.gov/pubmed/25598657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4196/kjpp.2014.18.6.447
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk